Uncategorized

Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease

by Business Wire • 2017/10/10 • 0 Comments

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics biotechnology company developing innovative therapies for MGD announced it has completed a $16 million Series B funding

Full Story →

← LivaNova’s New SenTiva Neurostimulator for Epilepsy FDA Approved

Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D., to President and Founder →

Post navigation